Sanofi (SNY)

41.31
0.22 0.54
NASDAQ : Health Technology
Prev Close 41.09
Open 41.25
Day Low/High 40.77 / 41.47
52 Wk Low/High 37.43 / 45.62
Volume 1.58M
Avg Volume 949.80K
Exchange NASDAQ
Shares Outstanding 2.58B
Market Cap 109.41B
EPS 2.00
P/E Ratio 23.56
Div & Yield 1.17 (2.73%)

Latest News

World Hemophilia Day: Sanofi Genzyme Donation Impacts Patients Across The Globe

World Hemophilia Day: Sanofi Genzyme Donation Impacts Patients Across The Globe

-- Nearly 17,000 patients in 40 developing countries have received treatment since donations began in 2015

Health Canada Issues Notice Of Compliance With Conditions (NOC/c) For LibtayoTM (cemiplimab), The First And Only Biologic For The Treatment Of Advanced Cutaneous Squamous Cell Carcinoma (CSCC)

Health Canada Issues Notice Of Compliance With Conditions (NOC/c) For LibtayoTM (cemiplimab), The First And Only Biologic For The Treatment Of Advanced Cutaneous Squamous Cell Carcinoma (CSCC)

Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) * CSCC is the second most common skin cancer in Canada i TORONTO, April 11, 2019 /CNW Telbec/ - Sanofi Genzyme, the Specialty Care Business Unit of sanofi-aventis Canda Inc, announced today that Health Canada has...

Sanofi Provides Unprecedented Access To Its Insulins For One Set Monthly Price

Sanofi Provides Unprecedented Access To Its Insulins For One Set Monthly Price

* Sanofi continues its commitment to helping reduce cost burden for people living with diabetes with first-ever insulin savings program

FDA Approves Dupixent® (dupilumab) For Moderate-to-severe Atopic Dermatitis In Adolescents

FDA Approves Dupixent® (dupilumab) For Moderate-to-severe Atopic Dermatitis In Adolescents

* Only therapy that targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis

FDA Expands Indication For Soliqua® 100/33

FDA Expands Indication For Soliqua® 100/33

* Soliqua 100/33 now approved as an add-on to diet and exercise for adults with type 2 diabetes

A Cereal Titan, a Jewelry Chain and Other Stocks That Look Good Short

SNY, RYN, I, SIG and K all recently were downgraded by TheStreet's Quant Ratings.

Sanofi And Regeneron Offer Praluent® (alirocumab) At A New Reduced U.S. List Price

Sanofi And Regeneron Offer Praluent® (alirocumab) At A New Reduced U.S. List Price

* This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DHX, EWBC, KE, MSON, OMN, RDWR, RNR, SEE Downgrades: AR, FTAI, K, RYN, SNY, TWO, VNDA Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

FDA Approves Cablivi® (caplacizumab-yhdp), The First Nanobody®-based Medicine, For Adults With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

FDA Approves Cablivi® (caplacizumab-yhdp), The First Nanobody®-based Medicine, For Adults With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

- First medicine approved in the U.S. specifically for the treatment of aTTP, a rare blood-clotting disorder

FDA Approves Use Of 0.5 ML Dose Of Fluzone® Quadrivalent (influenza Vaccine) In Children As Young As 6 Months Of Age

FDA Approves Use Of 0.5 ML Dose Of Fluzone® Quadrivalent (influenza Vaccine) In Children As Young As 6 Months Of Age

- The 0.5 mL dose is now approved for use in children 6 months through 35 months of age

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Do we have to run for the hills? Not necessarily.

FDA Approves Expanded Use Of Adacel® (Tdap) Vaccine For Repeat Vaccination

FDA Approves Expanded Use Of Adacel® (Tdap) Vaccine For Repeat Vaccination

* First and only vaccine approved in the U.S. for repeat vaccination 8 years or more after the first vaccination to help protect against tetanus, diphtheria and pertussis, offering flexibility for health care providers to help manage their immunization schedules(2)

Sanofi To Transfer U.S. Stock Exchange Listing To Nasdaq

Sanofi To Transfer U.S. Stock Exchange Listing To Nasdaq

PARIS, Dec. 18, 2018 /PRNewswire/ -- Sanofi today announced that it will be transferring the listing of its American Depositary Shares (ADS) from the New York Stock Exchange (NYSE) to The Nasdaq Global Select Market (Nasdaq) effective December 31, 2018,...

JPMorgan and Oracle Jump After Warren Buffett Buys Shares

JPMorgan and Oracle Jump After Warren Buffett Buys Shares

Warren Buffett's big buys of Oracle and JPMorgan have those stocks jumping Thursday.

ODYSSEY OUTCOMES Investigators Highlight At AHA That Praluent® (alirocumab) Injection Was Associated With Fewer Deaths From Any Cause

ODYSSEY OUTCOMES Investigators Highlight At AHA That Praluent® (alirocumab) Injection Was Associated With Fewer Deaths From Any Cause

* Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL

New England Journal Of Medicine Publishes Positive Detailed Results From Praluent® (alirocumab) Injection Cardiovascular Outcomes Trial

New England Journal Of Medicine Publishes Positive Detailed Results From Praluent® (alirocumab) Injection Cardiovascular Outcomes Trial

* Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)

Sanofi Q3 2018 Performance Confirms Return To Growth

Sanofi Q3 2018 Performance Confirms Return To Growth

PARIS , Oct. 31, 2018 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q3 2018 Change Change at CER 9M 2018 Change Change at CER IFRS net sales reported €9,392m +3.

FDA Grants Priority Review For Sanofi's Dengue Vaccine Candidate

FDA Grants Priority Review For Sanofi's Dengue Vaccine Candidate

BRIDGEWATER, N.J.

Breakthroughs In Breast Cancer Research

Breakthroughs In Breast Cancer Research

BRIDGEWATER, N.J.

Elon Musk Has Lost It and Must Consider Bringing In Facebook's Sheryl Sandberg

Elon Musk Has Lost It and Must Consider Bringing In Facebook's Sheryl Sandberg

Nvidia, nvidia, NVIDIA. In non-Nvidia news, the market faces some serious threats in the back half of 2018. And hey, about Elon Musk's latest interview ...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CFBK, CLDT, SNY, VET Downgrades: ADNT, AOI, BVN Initiations: AMMA Read on to get TheStreet Quant Ratings' detailed report:

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma

Insulin has been around since 1921. But there is no generic drug and four companies control the market. Now politicians, the AMA and patient groups are looking for lower prices.

Sanofi, Merck and J&amp;J Tout Lower Drug Prices

Sanofi, Merck and J&J Tout Lower Drug Prices

While a handful of drug companies say their average net prices have dropped, FDA Commissioner Scott Gottlieb announces a plan to encourage drug competition in the face of monopolies.

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs

Senior vice president Enrique Conterno says the Type-2 diabetes treatment is part of the fast-growing glucagon-like peptide-1 receptor agonists.

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

The tough news keeps coming at the generic drug company, which announced last week it was considering putting itself up for sale. Now the Justice Department wants a chat.

TheStreet Quant Rating: C+ (Hold)